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1. Introduction  
Salmonella enterica subsp. enterica serovar Typhi (hereafter referred to as Salmonella Typhi) is 
a Gram-negative enteric bacillus belonging to the family Enterobacteriaceae. It is a facultative 
anaerobe that is motile by peritrichous flagella. The bacterium is catalase positive, oxidase 
negative. It produces no gas when grown in Triple Sugar Iron (TSI) broth, which is used to 
differentiate it from other Enterobacteriaceae (Murray, 1994). 
The bacterium is restricted to humans and is not known to have a reservoir in animals. 
Thus, the transmission of S. Typhi has only been shown to occur from person to person via 
fecal-oral route. Infection of S. Typhi leads to the development of typhoid, or enteric fever. 
This disease is characterized by the sudden onset of a sustained and systemic fever, severe 
headache, nausea, and loss of appetite. Other symptoms include constipation or diarrhea, 
enlargement of the spleen, possible development of meningitis, and/or general malaise. The 
disease has caused many deaths in developing countries where sanitation is poor and is 
spread through contamination of water and undercooked food (Murray, 1994).  
Treatment of typhoid fever relies mainly on such antibiotics as chloramphenicol, ampicillin 
and trimethoprim-sulfamethoxazole (Rowe et al., 1997; Trung et al., 2007); however, the 
success of the antibiotic based therapeutic approach has currently been limited because of 
the emergence of multidrug resistant strains of S. Typhi. Owing to the development of 
bacterial resistance to chloramphenicol during the 1970s and 1980s, treatment with this drug 
was widely replaced by ampicillin and trimethoprim-sulfamethoxazole; however, by the 
1980s and 1990s, S. Typhi developed resistance simultaneously to all drugs used for first-
line treatment, namely, chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole 
(Trung et al., 2007). These multidrug resistant S.Typhi strains have been found to be 
responsible for numerous outbreaks in many countries in the Indian subcontinent, Southeast 
Asia, and Africa (Rowe et al., 1997). In light of the evidence of the rapid global spread of 
drug resistant S. Typhi strains, the need to find new antibiotics to treat diseases caused by 
the bacteria is of paramount importance. However, the past record of rapid emergence of 
resistance to newly introduced antibiotics indicates that even new families of antibiotics will 
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have a short life expectancy (Coates et al., 2002). For this reason, researchers are increasingly 
turning their attention to alternative therapeutic approaches to combat drug resistant S. 
Typhi. One of the promising approaches is bacteriophage therapy or phage therapy. 
Bacteriophages or phages are viruses that infect bacteria. Lytic or virulent bacteriophages 
have been considered to be a new class of antibacterial agents because they undergo rapid 
growth, disrupt bacterial metabolism and reproduction, and lyse the bacterial cells. They 
have been used for therapeutic purposes since the 1920s. Several studies have shown that 
bacteriophages could be used successfully for therapeutic purposes both in humans and 
animals (Bruttin & Brussow, 2005; Chhibber et al., 2008; Deresinski, 2009; Nakai & Park, 
2002). In addition, there have been several reports showing the ability of lytic 
bacteriophages to kill drug resistant bacteria (Capparelli et al., 2007; Thamniamton et al., 
2010; Vinodkumar et al., 2005). Therefore, it is of interest to find a bacteriophage for use as a 
therapeutic agent to control drug resistant S. Typhi. 
In this study, a bacteriophage specific to drug resistant S. Typhi was isolated from hospital 
wastewater. It was also characterized with respect to host range, adsorption, thermal and 
pH sensitivity, one step growth, and morphology, genome and protein composition. The 
bacteriophage from this study may be useful as a potential therapeutic agent for controlling 
drug resistant S. Typhi infections.   
2. Materials and methods 
2.1 Bacterial strains and culture conditions 
The bacterial strain used as the indicator strain for the isolation, propagation, and 
characterization of the bacteriophage named PPST1 was drug resistant Salmonella enterica 
subsp. enterica serovar Typhi strain SSH1 (hereafter referred to as S. Typhi SSH1) which was 
kindly donated by Sappasitiprasong Hospital, Ubon Ratchathani, Thailand. The bacterial 
strain was confirmed as S. Typhi by the API 20 E test kit (bioMerieux Industry, Hazelwood, 
MO, USA). Antibiotic susceptibility testing by Kirby-Bauer’s method revealed that S. Typhi 
SSH1 was resistant to most of the commonly-used drugs including chloramphenicol, 
ampicillin, trimethoprim, tetracycline, streptomycin, sulfanilamideand ciprofloxacin. 
Bacterial strains used to test the host range of the bacteriophage PPST1 are listed in Table 1. 
All of them were obtained from the American Type Culture Collection (ATCC). 
All bacteria were maintained on Brain Heart Infusion (BHI) agar (Oxoid, Wesel, Germany). 
Fresh colonies were cultured and subcultured in BHI broth at 37°C. Stock cultures of all 
bacteria were stored as a frozen culture at -80ºC in BHI broth containing 20% glycerol 
(vol/vol). 
2.2 Bacteriophage isolation and purification 
The water sample for bacteriophage isolation was collected from wastewater treatment tank 
located at Sappasitiprasong Hospital, Ubon Ratchathani, Thailand. The sample was stored at 
4°C overnight to allow larger suspended sediments to settle out. The crudely clarified 
sample was centrifuged at 4,500 xg for 10 min to remove bacterial cells and debris. The 
supernatant was passed through a 0.22-μm-pore-size membrane filter (SartoriusAG, 
Gottingen, Germany). For bacteriophage enrichment, the filtrate was added to an equal 
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volume of double strength BHI broth containing log phase S. Typhi SSH1 cells (final 
concentration of 106 CFU/ml). After incubation at 37°C overnight, the culture was 
centrifuged at 4,500 xg for 10 min and the supernatant was filtered through a 0.22-μm-pore-
size membrane filter. The presence of a lytic phage in the filtrate was examined by using the 
double layer method with some modifications (Paterson et al., 1969). One hundred μl of the 
filtrate was mixed with 400 μl of a log phase culture of S. Typhi SSH1 and incubated at 37°C 
for 30 min. The mixture was added into 4.5 ml of molten BHI soft agar (0.7% agar) which 
was already cooled down to 50°C, mixed gently, and poured onto a BHI agar plate (1.5% 
agar). The plate was left to stand at room temperature for 30 min to allow the top agar to 
solidify. The presence of a lytic bacteriophage in the form of plaques was detected after 
incubation of the plate at 37°C overnight. 
For bacteriophage purification, a single plaque was picked with a sterile glass Pasteur pipette, 
and put into a log phase culture of S. Typhi SSH1. After incubated at 37°C overnight, the 
bacteriophage-host mixture was centrifuged at 4,500 xg for 10 min and filtered through a 0.22-
μm-pore-size membrane filter. The filtrate was subjected to the double layer method as 
mentioned above. Three repeated rounds of single plaque isolation and re-inoculation were 
performed. The bacteriophage was eluted from the final resulting plate by adding 5 ml of SM 
buffer (50 mM Tris-HCl, pH 7.5, 99 mM NaCl, 8 mM MgSO4, 0.01% gelatin) on top of the plate 
and incubated at room temperature for 4 h with shaking. The bacteriophage containing buffer 
retrieved from the plate was centrifuged at 4,500 xg for 10 min and filtered through a 0.22-μm-
pore-size membrane filter. The resulting filtrate was called bacteriophage suspension. 
2.3 Bacteriophage titer determination 
The bacteriophage containing solution was serially diluted in SM buffer. Each dilution was 
subjected to plaque assay using the double layer method as mentioned earlier. Plaques were 
counted in the plate containing 50-300 plaques and expressed as plaque forming unit per 
milliliter (PFU/ml). 
2.4 Bacteriophage host range determination 
The spot test method described by Chang et al. (2005) was used for bacteriophage host range 
determination using the bacteria listed in the Table 1 as hosts. Each bacterial strain was 
grown overnight in BHI broth. One hundred μl of the culture was mixed well with 4 ml of 
BHI soft agar (0.7% agar) and then overlaid on the surface of the BHI agar (1.5% agar). After 
solidication, 10 μl of the bacteriophage suspension was spotted onto the top agar layer, 
which was then incubated at 37°C overnight. Bacterial sensitivity to the bacteriophage was 
notified by a clear zone at the spot where the phage suspension was deposited.  
2.5 Bacteriophage adsorption study 
The bacteriophage adsorption was studied according to the protocol of Lu et al. (2003) with 
some modifications. A S. Typhi SSH1 culture with the concentration of 108 CFU/ml was 
infected with the bacteriophage suspension to give a multiplicity of infection (MOI) of 0.01 
and incubated at 37C. Aliquots were taken at 5 min intervals (up to 30 min) after infection 
and immediately centrifuged at 4,500 xg for 10 min to sediment the bacteriophage-adsorbed 
cells. filtered through a 0.22-μm-pore-size membrane filter. Filtrates were subjected to 
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determination of titer of unadsorbed bacteriophages (residual titer) by the double layer 
method as mentioned earlier. BHI broth containing only bacteriophage was used as a 
control. The percentage of adsorption was calculated as follows: [(control titer-residual 
titer)/control titer] x 100%. 
2.6 Thermal and pH sensitivity test 
The sensitivity of bacteriophage PPST1 to temperature was examined as follows. Nine 
hundred μl of sterile deionized water was preheated to a desirable temperature, ranging 
from 50°C to 90°C. One hundred μl of the bacteriophage suspension was added to the 
preheated water to obtain the final bacteriophage concentration of about at 106 PFU/ml. 
After heating at the assigned temperatures for 30 min, the solutions were placed in an ice 
bath. Surviving bacteriophage titer was assayed by the double layer method. 
The sensitivity of bacteriophage PPST1 to pH was also examined. The bacteriophage (at the 
final concentration of 106 PFU/ml) was incubated overnight at 37°C in phosphate buffered 
saline (135 mM NaCl, 1.3 mM KCl, 0.5 mM KH2PO4, 3.2 mM Na2HPO4, pH 7.4), adjusted in 
steps of 1 pH unit from pH 2 to 12 using HCl or NaOH as required. Upon re-adjustment to 
pH 7, the double layer method was performed to determine bacteriophage titer.  
2.7 Study of one-step growth kinetics 
One step growth experiment was performed as described by (Caso et al., 1995) with some 
modifications. Briefly, 10 ml of log phase culture of S. Typhi SSH1 was harvested by 
centrifugation at 4,500 xg for 10 min and resuspended in 5 ml of fresh BHI broth in order to 
obtain a final concentration of 108 CFU/ml. To this suspension, 5 ml of the bacteriophage 
suspension was added in order to have a MOI of 0.01 and the bacteriophage was allowed to 
adsorb for 30 min at 37°C. The mixture was centrifuged at 4,500  g for 10 min, and the 
pellets containing infected cells were resuspended in pre-warmed (37C) BHI broth, 
followed by incubation at 37C. Samples were taken at 10-min intervals (up to 3 h) and 
immediately diluted, and bacteriophage titers were determined by the double layer method.  
2.8 Examination of bacteriophage morphology 
The morphology of bacteriophage PPST1 was examined by transmission electron 
microscopy. Bacteriophage particles were fixed by mixing 25 μl of the bacteriophage 
suspension with 25 μl of 50% glutaraldehyde in 4% paraformaldeyde. A 5-μl aliquot of this 
mixture was placed on a carbon Formvar-coated copper grid (Proscitech, Brisbane, 
Queenland, Australia) and allowed to adsorb for 5 min at room temperature. The 
bacteriophage was negatively stained with 0.5% uranyl acetate for 2 min then inspected 
with a Philips EM 300 electron microscope (Philips, Eindhoven, the Netherlands) operated 
at 60 kV. The bacteriophage size was determined from the average of five independent 
measurements. 
2.9 Analysis of bacteriophage proteins 
The protein composition of bacteriophage PPST1 was examined by sodium dodecyl sulfate-
polyacrylamide gel eectrophoresis (SDS-PAGE) using NuPAGE Novex gel system 
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(Invitrogen, Carlsbad, CA, USA). A 26-μl aliquot of the bacteriophage suspension was 
mixed with 10 μl of sample buffer and 4 μl of reducing agent. The mixture was heated in 
boiling water for 10 min and then subjected to electrophoresis on a 4-12% Bis-Tris gel at 200 
V and 120 mA for 35 min. The protein bands were stained with Coomassie blue G-250 
(Sigma-Aldrich, St. Louis, MO, USA), followed by destaining with a solution containing 50% 
methanol and 1% acetic acid.  
2.10 Analysis of bacteriophage nucleic acid  
Bacteriophage nucleic acid was extracted by using PureLink Viral RNA/DNA Mini Kit 
(Invitrogen, Carlsbad, CA, USA) according to the protocol provided by the manufacturer. 
The purified nucleic acid was tested for sensitivity to Ribonuclease A, Nuclease S1 and 
restriction enzyme PstI (all from Sigma-Aldrich, St. Louis, MO, USA), according to the 
supplier’s recommendations. The results were analyzed by 0.8% agarose gel electrophoresis. 
The genome size of the bacteriophage PPST1 was determined by pulse-field gel 
electrophoresis (PFGE) of the purified bacteriophage nucleic acid. The electrophoresis was 
carried out with 0.8% agarose gel in 0.5x Tris-borate-EDT buffer at 15°C for 15 h, using 
switch time ramped from 1 to 12 s and a voltage of 6 V/cm. The PFGE size standard used 
was Low range PFG marker (New England Biolabs, Ipswich, MA, USA). 
3. Results 
3.1 Bacteriophage isolation 
A bacteriophage was isolated from the hospital wastewater by the double layer method 
using S. Typhi SSH1 as a host bacterial strain. The bacteriophage produced clear plaques on 
the lawn of the host bacterial strain, indicating that it was a lytic or virulent bacteriophage. 
The plaques were small with an average diameter of 1 mm (Fig. 1), and the isolated 
bacteriophage was designated PPST1.  
 
Fig. 1. Plaques on S. Typhi SSH1 lawn (a) and transmission electron micrograph (b) of 
bacteriophage PPST1. Bar = 50 nm 
b. a. 
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3.2 Bacteriophage host range 
Specifictity of bacteriophage PPST1 to a variety of bacteria was examined by the spot test 
method. Of all 23 bacterial strains used in this experiment, only S. Typhi SSH1, S. Typhi 
ATCC 19430, S. Typhi ATCC 19214 were susceptible to the bacteriophage as shown in Table 
1. On the other hand, the rest of the tested bacterial strains used in this study were not 
sensitive to the bacteriophage. Among the three sensitive bacterial hosts, two of them, S. 
Typhi SSH1 and S. Typhi ATCC 19214, are drug resistant strains. These results suggested 
that the bacteriophage had a broad host range with specificity to S. Typhi and the specificity 
of the bacteriophage was not influenced by the drug-resistance properties of the hosts. 
 
Bacteria Lysisa 
Campylobacter jejuni ATCC 29428 - 
Enterobacter aerogenes ATCC 13048  
Enterococcus faecalis ATCC 51575 (vancomycin resistant) - 
Escherichia coli ATCC 11229 - 
Escherichia coli O157:H7 ATCC 35150 - 
Klebsiella pneumoniae ATCC 4352 - 
Listeria monocytogenes ATCC 19111 - 
Pseudomonas aeruginosa ATCC 15442 - 
Salmonella enterica serovar Choleraesuis ATCC 6958 - 
Salmonella enterica serovar Derby ATCC 6960 - 
Salmonella enterica serovar Enteritidis ATCC 4931 - 
Salmonella enterica serovar Heidelberg ATCC 8326 - 
Salmonella enterica serovar Paratyphi A ATCC 9150 - 
Salmonella enterica serovar Typhi SSH1 (multidrug resistant) + 
Salmonella enterica serovar Typhi ATCC 19430 + 
Salmonella enterica serovar Typhi ATCC 19214 (multidrug resistant) + 
Salmonella enterica serovar Typhimurium ATCC 6994 - 
Salmonella enterica serovar Typhimurium ATCC 700408 (multidrug resistant) - 
Salmonella enterica serovar Typhisuis ATCC 8321 - 
Shigella flexneri ATCC 29903 - 
Staphylococcus aureus ATCC 6538 - 
Staphylococcus aureus ATCC 33592 (methicillin resistant) - 
Streptococcus pyogenes ATCC 19615 - 
a + = clear zone form, - = no clear zone formed 
Table 1. Bacterial strains used in this study and their sensitivity to bacteriophage PPST1 
3.3 Bacteriophage adsorption 
The adsorption rate of bacteriophage PPST1 on S. Typhi ST1 is shown in Fig 2. Most of the 
bacteriophage particles were rapidly adsorbed to host cells within the first 10 minutes of the 
observation period; after which, the bacteriophage particles were adsorbed into the host cells 
at a relatively slow rate. Almost all of the bacteriophage particles were adsorbed into the host 
cells within 30 minutes. The results demonstrated that ca. 80%, 90% and 98% of bacteriophage 
PPST1 particles adsorbed to the host cells within 10 min, 20 min and 30 min, respectively. 
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Fig. 2. Adsorption of bacteriophage PPST1 on S. Typhi SSH1 cells 
3.4 Thermal and pH sensitivity 
Thermal lability of bacteriophage PPST1 was investigated by thermal treatments at 50, 60, 
70, 80 and 90C for 30 min (Table 2). At 50C, only a small reduction of the bacteriophage 
was observed. In contrast, the bacteriophage titers decreased considerably at 60 and 70C. 
The higher temperature resulted in fewer bacteriophage titers. Heating at 80 and 90C for 30 
min completely inactivated the bacteriophage, thus phage titer could not be detected in the 
samples.  
The stability of bacteriophage PPST1 was also investigated by incubating the bacteriophage 
overnight in a phosphate buffered saline solution at pH ranging from 2 to 12. The 
bacteriophage maintained its infectivity when incubated in a pH range of from 4 to 10. In 
contrast, the bacteriophage lost its infectivity completely at pH 3 or below as well as at pH 
11 or above. The highest stability of bacteriophage was observed at pH 7 (Table 2).  
3.5 One step growth kinetics 
Multiplication parameters of the lytic cycle of bacteriophage PPST1 including latent period, 
burst period and burst size were determined from the dynamic change in the number of 
bacteriophage during one replicative cycle (Fig. 3). It was determined that bacteriophage 
PPST1 had latent and burst periods of ca. 30 and 150 min, respectively. The burst size 
estimated from the one-step growth curve was about 79 PFU/infected cell (Fig. 3). 
3.6 Morphology, genome and protein composition 
Morphological characterization of bacteriophage PPST1 was examined by transmission 
electron microscopy. It was shown that the bacteriophage had an icosahedral head (64 ± 2.4 
nm in diameter) with a noncontractile tail of 157 ± 8.6 nm long and 12 ± 0.6 nm wide. No 
collar or tail appendages were observed (Fig. 1). 
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Treatment 
Initial bacteriophage 
concentration 
(log PFU/ml) 
Final bacteriophage 
concentration 
(log PFU/ml)a 
Heat (for 30 min) 
    50 °C 
    60 °C 
    70 °C 
    80 °C 
    90 °C 
 
6.09 
6.04 
5.97 
6.08 
6.00 
 
5.57 
3.62 
2.46 
- 
- 
pH (for 1 h) 
    2 
    3 
    4 
    5 
    6 
    7 
    8 
    9 
    10 
    11 
    12 
 
6.02 
5.98 
6.08 
6.00 
6.02 
6.04 
5.99 
6.03 
6.02 
5.97 
6.00 
 
- 
- 
3.96 
3.51 
4.83 
5.89 
4.93 
3.73 
2.67 
- 
- 
a = undetectable 
Table 2. Sensitivity of bacteriophage PPST1 to temperature and pH. 
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Fig. 3. One-step growth curve of bacteriophage PPST1. 
The nucleic acid extracted from bacteriophage PPST1 was examined for its sensitivity to 
different nucleic acid digesting enzymes. It was found that the nucleic acid could not be 
digested either by Ribonuclease A or Nuclease S1; however, it was sensitive to the restriction 
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enzyme PstI (Fig. 4). The size of the nucleic acid as revealed by the pulsed-filed gel 
electrophoresis was ca. 70 kb. 
The protein composition of bacteriophage PPST1 was analyzed by SDS-PAGE and the result 
is shown in Fig. 5. Four protein bands were clearly detected in the SDS-PAGE gel. Based on 
sizes of protein standard SeeBlue Plus 2 (Invitrogen, Carlsbad, CA, USA), their estimated 
molecular masses were 81, 32, 24 and 15 kDa. 
 
Fig. 4. Agarose gel electrophoresis of bacteriophage PPST1 nucleic acid. Lane 1, lambda 
DNA digested with HindIII marker; lane 2 uncut PPST1 nucleic acid; lane 3, PPST1 nucleic 
acid digested with Ribonuclease A; lane 4, PPST1 nucleic acid digested with Nuclease S1, 
lane 5, PPST1 nucleic acid digested with PstI. 
 
Fig. 5. SDS-PAGE analysis of bacteriophage PPST1 proteins. Lane 1, the protein standard 
SeeBlue Plus2, lane 2, proteins of bacteriophage PPST1. 
4. Discussion  
Typhoid fever caused by S. Typhi is a major pubic health problem worldwide, especially in 
developing countries. Although its incidence in the developed countries has been declining, 
the disease is still a frequent cause of death in parts of the world with poor sanitation 
(Murray, 1994). Until just recently, antibiotics were widely used to control S. Typhi 
infections; however, the emergence of antibiotic resistant S. Typhi in reducing drug efficacy 
1 2 3 4 5
23,130 kb 
9,416 kb 
6,557 kb 
4,361 kb 
2,322 kb 
2,027 kb 
1 2
188 kDa
98 kDa
62 kDa
49 kDa
38 kDa
28 kDa
17 kDa
14 kDa
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has led to a need for alternatives to antibiotics in controlling infections as a result of the 
pathogenic bacteria. Bacteriophage therapy is one of the promising alternatives to control 
infections caused by drug resistant bacteria. This may be due to the fact that bacteriophages 
and antibiotics have different mechanisms of action (McAuliffe et al., 2007). Besides the 
ability to inhibit the growth of drug resistant bacteria, many attributes of bacteriophages 
make them more favorable than antibiotics for therapeutic purposes. They infect only their 
specific hosts, having no harm on normal microflora, and because of their host dependent 
multiplication, bacteriophages increase their numbers at the sites of infection, thereby 
increasing therapeutic efficacy. After their hosts are inactivated, bacteriophages tend to be 
rapidly cleared from bodies of treated organisms (Carlton, 1999; Matsuzaki et al., 2005) by 
innate immune mechanisms. Therefore, bacteriophage therapy may be considered an 
effective and safe therapeutic approach.  
Bacteriophages generally reside in environments that are habitats for their host bacteria 
(McLaughlin et al., 2006; Sundar et al., 2009). Wastewater from Sappasitthiprasong hospital, 
Ubon Ratchathani, Thailand was ideal for isolation of bacteriophages in this study since the 
drug resistant S. Typhi strain SSH1 used as the main host in the present bacteriophage 
screening  is a clinical strain isolated from a patient admitted to the hospital. When 
screening for bacteriophages to be used in bacteriophage therapy, bacteriophages with a 
broad host range spectrum within a species are more preferable because they can be 
effective against a large variety of a particular species. The narrow host specificity of 
bacteriophages can cause complexity in preparation of therapeutic phages. In some cases, 
combinations of several bacteriophages are required for therapeutic application. In this 
study, bacteriophage PPST1 was showed to be lytic to all of the tested S. Typhi strains, but 
not any other tested bacteria. Furthermore, among the sensitive bacterial strains, two were 
multi-drug resistant. S Typhi SSH1 is resistant to chloramphenicol, ampicillin, 
trimethoprim, tetracycline, streptomycin, sulfanilamide and ciprofloxacin while S Typhi 
ATCC 19214 is resistant to chloramphenicol, tetracycline and streptomycin. These results 
suggest that bacteriophage PPST1 is a potential candidate for use as a therapeutic agent to 
control infectious diseases caused by drug resistant S. Typhi. Finding a lytic bacteriophage 
with a broad host range is not unusual. A number of studies have reported the isolation of 
lytic bateriophages with a broad host range. Vinod et al. (2006) isolated a Vibrio harveyi 
bacteriophage from shrimp farm water, which was virulent to all 50 strains of V. harveyi 
tested that were originally isolated from different sources such as seawater, hatchery water, 
shrimp farm water and sediment. Moreover, some bacteriophages were reported to be lytic 
to bacteria in more than one genera. For example, phage KPO1K2 infected several strains of 
Klebsiella pneumoniae and Escherichia coli (Verma et al., 2009). 
From previous studies, Salmonella bacteriophages were found to be heterogeneous, 
comprising all of the three families of tailed bacteriophages, including Siphoviridae, 
Myoviridae and Podoviridae (Demczuk et al., 2004; McLaughlin, 2006; De Lappe et al., 2009). 
The criteria commonly used for the classification of bacteriophages to a particular group are 
bacteriophage genetic and morphological characteristics. The genome of bacteriophage 
PPST1 was double stranded DNA because it was resistant to Nuclease S1, a single stranded 
DNA digesting enzyme, and Ribonuclease A, a RNA digesting enzyme, but sensitive to the 
restriction enzyme PstI, a double stranded DNA digesting enzyme. Transmission electron 
microscopy revealed that the bacteriophage was a tailed bacteriophage with an icosahedral 
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head and a long noncontractile tail. Based on these characteristics, bacteriophage PPST1 can 
be tentatively classified as a member of the family Siphoviridae, according to the 
International Committee on Taxonomy of Viruses (Ackermann, 2005). There are several 
previously studied S. Typhi bacteriophages that have never been classified into a particular 
family due to the lack of genetic or morphological characteristics. The lytic bacteriophage 
specific to S. Typhi DMS 5784 was found to have an icosahedral head that was ca. 44 to 47 x 
43 to 51 nm in diameter and a very short tail. Since its genomic characteristic has been 
studied, no classification of the bacteriophage has ever been reported (Neukdee,  2007). The 
S. Typhi bacteriophage j2 studied by Mise et al. (1981) is a DNA lysogenic bacteriophage. 
The lack of its morphological information has impeded the classification of the 
bacteriophage. 
Variations in nucleic acid sequence and numbers of genes and proteins of bacteriophages in 
the family Siphoviridae have been reported (Rohwer and Edwards, 2002). In this study, four 
proteins with molecular masses ranging from 15 to 81 kDa were identified by SDS-PAGE 
analysis. However, their amino acid sequences and functions are still unknown. A detailed 
nucleic acid sequence analysis and identification of the open reading frames corresponding 
to the observed structural proteins are the subjects of future research. 
Several studies have demonstrated that thermal and pH stability of bacteriophages varied 
depending on types of bacteriophage; therefore, it is of interest to investigate the stability of 
bacteriophage PPST1 in a wide temperature and pH range. These results demonstrate that 
bacteriophage PPST1 is stable in a broad pH range (4-10) and at a temperature as high as 
70°C for at least 3 min. These morphological characteristics may be useful in broad 
applications of bacteriophage therapy.  
In conclusion, the data obtained from the present study clearly indicates that the 
bacteriophage PPST1 is a lytic bacteriophage capable of killing several strains of S. Typhi, 
including drug resistant strains. This property of the bacteriophage, together with its 
stability at a high temperature and over a wide pH range, makes bacteriophage PPST1 a 
potential alternative to antibiotics as a therapeutic agent for infections of drug resistant S. 
Typhi. Future research is needed to elucidate the most suitable condition for the application 
of this characterized bacteriophage in treating experimentally-induced drug resistant S. 
Typhi infection in animal models.  
5. Summary 
The emergence of drug resistant Salmonella Typhi has limited the efficacy of antibiotic based 
therapeutic approach. Bacteriophage therapy has recently been considered a promising 
approach to control infections caused by drug resistant bacteria. In this study, a lytic 
bacteriophage, specific to drug resistant S. Typhi strain SSH1, was isolated from hospital 
wastewater. The bacteriophage, designated PPST1, had broad host range within the species 
S. Typhi. It was lytic against all of the tested S. Typhi strains, but not any other tested 
bacteria. The bacteriophage was completely inactivated at 80 and 90°C for 30 min but was 
stable at 50 °C for 30 min and over a wide pH range (4 to 10). Approximately 80%, 90% and 
98% of bacteriophage particles adsorbed to the host cells within 10, 20 and 30 min after 
infection, respectively. One-step growth kinetics of the bacteriophage showed that the latent 
and burst periods were 30 and 150 min, respectively, and the burst size was about 79 
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PFU/infect cell. As shown by transmission electron microscopy, the bacteriophage had an 
icosahedral head of ca. 64 nm in diameter and a long noncontractile tail of ca. 157 nm long 
and 12 nm wide. Its genome was double stranded DNA, 70 kb in size. It was classified as a 
member of the family Siphoviridae. A total of 4 bacteriophage proteins with molecular 
masses of 15, 24, 32 and 81 kDa were detected by sodium dodcyl sulfate-polyacrylamide gel 
electrophoresis. Knowledge of the properties of bacteriophage PPST1 may be useful for the 
development of the bacteriophage to use as therapeutic agents against infections as a result 
of drug resistant S. Typhi 
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